Firms

Lightswitch Capital

Lightswitch Capital

New York, New York, United States

Lightswitch Capital is a New York investment manager and long-term partner to private healthcare companies. Its legal adviser is Lightswitch Capital Management, L.P., a Delaware limited partnership reporting to the SEC as an exempt reporting adviser under CRD319223. Its healthcare investments include precision neuropsychiatry company Alto Neuroscience, gene therapy engineering company Kriya Therapeutics and antibody-platform company Hinge Bio. Current regulatory disclosures identify Christopher Nixon Cox as chief executive officer and general partner, Bo Cui as chief operating officer, and Pamela Louise Rockley as chief compliance officer. Rockley provides compliance services through her consulting business; she is included as a regulatory officer rather than an investment partner. The adviser reports one Cayman Islands private fund, Lightswitch Capital Fund I, L.P., with Lightswitch Capital GP, LLC as general partner. Public fund assets do not establish its final commitments or closing date. The firm is distinct from unrelated businesses using the Lightswitch name.

Founded
—
Type
Venture capital

Funds1

  • Lightswitch Capital Fund I, L.P.—

    Current SEC adviser filing identifies a Cayman Islands private fund, private fund ID805-7817892754, with Lightswitch Capital GP, LLC as general partner. It is neither a master nor a feeder fund. The filing reports USD34,596,219 gross asset value and two beneficial owners; this is not a documented final capital close. Total cash commitments and closing date remain undisclosed. Alto securities filings identify this exact vehicle as a shareholder; manager-affiliated transaction totals are qualified separately.

Team

Operations and support

Bo CuiBo CuiChief Operating Officer
Christopher Nixon CoxChristopher Nixon CoxChief Executive Officer and General Partner
Pamela Louise RockleyChief Compliance Officer (external compliance-services qualification)

Co-investing

Investments